TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nanobiotix ( (NBTX) ) has issued an announcement.
On October 1, 2025, Nanobiotix announced promising initial data from a Phase 1 study evaluating JNJ-1900 (NBTXR3) for esophageal cancer treatment. The study, presented at the ASTRO 2025 Annual Meeting, showed a high disease control rate of 85% and an objective response rate of 69% among 13 patients, with the treatment being well-tolerated. This development could potentially open new indications for JNJ-1900 (NBTXR3) and enhance Nanobiotix’s positioning in the oncology market, offering a novel approach that may reduce the need for invasive procedures like esophagectomy.
The most recent analyst rating on (NBTX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock’s strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company’s broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, and listed on Euronext Paris and Nasdaq. The company focuses on pioneering physics-based therapeutic approaches, particularly in oncology, bioavailability, and disorders of the central nervous system. It owns more than 25 umbrella patents and has subsidiaries in Cambridge, Massachusetts, among other locations.
Average Trading Volume: 36,214
Technical Sentiment Signal: Buy
Current Market Cap: $793.2M
See more data about NBTX stock on TipRanks’ Stock Analysis page.